Renin inhibitors are one of four classes of compounds that affect the renin-angiotensin-aldosterone system. Renin inhibitors produce vasodilation by inhibiting the activity of renin, which is responsible for stimulating angiotensin II formation. Renin is a proteolytic enzyme that is released by the kidneys in response to sympathetic activation, hypotension, and decreased sodium delivery to the distal renal tubule. Aliskiren (INN) (trade names Tekturna, US; Rasilez, UK and elsewhere) is the first in a class of drugs called direct renin inhibitors. Its current licensed indication is essential (primary) hypertension.
USA is still the largest consumption region of Tekturna, occupied about 56% market share globally, with revenue 39.21 million USD in 2017. At the same time, Asia will see the considerable growth since Noden Pharma DAC had successfully entered into an agreement with Orphan Pacific (Japan) and Lee’s Pharmaceutical Holdings Limited (China).
The global Renin-Inhibitors market is valued at 69 million US$ in 2018 and will reach 120 million US$ by the end of 2025, growing at a CAGR of 6.8% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Renin-Inhibitors market based on company, product type, end user and key regions.
This report studies the global market size of Renin-Inhibitors in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Renin-Inhibitors in these regions.
This research report categorizes the global Renin-Inhibitors market by top players/brands, region, type and end user. This report also studies the global Renin-Inhibitors market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Market size by Product
Market size by End User
Age below 45
Age above 65
Market size by Region
Central & South America
Rest of Central & South America
Middle East & Africa
The study objectives of this report are:
To study and analyze the global Renin-Inhibitors market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Renin-Inhibitors market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Renin-Inhibitors companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Renin-Inhibitors submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Renin-Inhibitors are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Tablet). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Renin-Inhibitors market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.